Almirall and Absci announce AI drug discovery partnership to rapidly develop novel treatments
VANCOUVER, Wash. and BARCELONA, Spain, Nov. 14, 2023 (GLOBE NEWSWIRE) —
Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, and Almirall S.A. (BME: ALM), a global biopharmaceutical company focused on medical dermatology, have announced a collaboration that will expand Absci’s de novo AI drug creation portfolio into dermatology and accelerate discovery for broader chronic inflammatory diseases.
The partnership
This new partnership will combine Absci’s cutting-edge AI technology with Almirall’s expertise in medical dermatology to rapidly develop novel treatments for a variety of skin conditions and chronic inflammatory diseases. By leveraging Absci’s AI drug creation platform, the two companies aim to streamline the drug discovery process and bring innovative therapies to patients faster than ever before.
“We are excited to partner with Almirall to harness the power of AI and accelerate the development of groundbreaking treatments for dermatological and inflammatory conditions,” said the CEO of Absci Corporation. “This collaboration represents a significant step forward in our mission to revolutionize drug discovery and improve patient outcomes.”
The impact
With this partnership, Absci and Almirall are poised to make a significant impact in the field of dermatology and chronic inflammatory diseases. By combining their expertise and resources, the two companies have the potential to develop breakthrough therapies that could improve the lives of millions of patients worldwide.
“We believe that this collaboration has the potential to transform the treatment landscape for dermatological and inflammatory conditions,” said the CEO of Almirall S.A. “By harnessing the power of AI, we hope to identify novel drug candidates faster and more efficiently, ultimately bringing new treatment options to patients in need.”
How this partnership will affect me
As a patient, this partnership between Absci and Almirall holds the promise of bringing new and innovative treatments to market faster than ever before. If you suffer from dermatological or chronic inflammatory conditions, this collaboration could lead to the development of more effective therapies that could improve your quality of life.
How this partnership will affect the world
This partnership has the potential to have a far-reaching impact on the world of healthcare. By accelerating the drug discovery process and bringing new treatments to market more quickly, Absci and Almirall could help address unmet medical needs and improve patient outcomes on a global scale. This collaboration could pave the way for future innovations in AI-driven drug discovery and revolutionize the way we approach medical treatment.
Conclusion
The partnership between Absci Corporation and Almirall S.A. marks a significant step forward in the advancement of AI-driven drug discovery. By combining their expertise and resources, the two companies are poised to develop novel treatments for dermatological and chronic inflammatory conditions that could benefit patients worldwide. This collaboration has the potential to revolutionize the field of healthcare and improve outcomes for millions of individuals in need of innovative therapies.
